R&D channel feed – Endpoints News

R&D channel feed

Novo takes on gut-brain axis discovery with Kallyope, focusing on obesity and diabetes

7 years ago

GSK vs Gilead: Heavyweight HIV fight will come down to a big showdown in Amsterdam next month

7 years ago

Anika Therapeutics shares crater as its 2nd PhIII OA study flops -- drug combo pales in comparison to a steroid

7 years ago

Vertex expands its San Diego R&D hub, adding a new wing for collaborators as it centers on CF research

7 years ago

Building up its rare obesity pipeline, Rhythm Pharma to raise $150M

7 years ago

Sarepta leads off Duchenne MD gene therapy study with a ‘home run’ on efficacy — but can they deliver in 2 years?

7 years ago

Valeant nosedives on CRL for plaque psoriasis, raising concerns over touted $1B pipeline

7 years ago

Spinraza rival? With DMD flops in the rearview mirror, PTC Therapeutics posts strong SMA data

7 years ago

Ziopharm gets hit with a clinical hold as FDA red lights human study using their fast-built CAR-T

7 years ago

Catalyst Bio shares bashed as neutralizing antibodies force investigators to freeze hemophilia cohort work

7 years ago

After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom

7 years ago

Daiichi says it’s ready to change the standard of care for acute myeloid leukemia — but it’s a work in progress

7 years ago

Winners and losers at #EHA18: Shares mostly slide as data from a range of prominent biotechs fail to wow investors

7 years ago

Teva hit by another PhIII setback on CGRP pain drug fremanezumab, but there’s no pulling back now as rivals race ahead

7 years ago

In the glare of an intense gene therapy spotlight, bluebird continues to tout each small step forward for its pioneering LentiGlobin

7 years ago

Researchers outline another big disease target for Novartis’ canakinumab as drug slashes rate of gout flares

7 years ago

GSK, ViiV offer sneak peek of PhIII data on in-house two-drug HIV combo, touting non-inferiority

7 years ago

New Jersey dangles tax savings in front of Teva in bid to bag US HQ as revamp costs 200-plus jobs

7 years ago

Eisai is building a bespoke Cambridge research center with a $100M-plus plan to find new ways to tackle Alzheimer's

7 years ago

Flex sends out an SOS signal, scrapping studies and slashing staff as it hunts a survival strategy — shares crater

7 years ago

Little vTv Therapeutics adds another round of bad data on Alzheimer's drug, but they still love their chances

7 years ago

Galmed's stock rockets up as execs tout a mixed set of NASH data

7 years ago

Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs

7 years ago

PhIII Alzheimer’s drug goes bust — and a major setback at Eli Lilly and AstraZeneca may doom the class

7 years ago

First page Previous page 269 270 271272273 274 275 Next page Last page